Generated static export from Obsidian-friendly vault markdown
ClinPharm Vault

EP262

Overview

  • Priority class: MRGPRX2
  • Mechanistic bucket: MRGPRX2-pathway program
  • Sponsor: Escient Pharmaceuticals, Inc
  • Development focus: Completed or historical urticaria development represented in current raw-source layer
  • Indications represented in current raw sources: Chronic Inducible Urticaria, Chronic Spontaneous Urticaria

Strategy readout

  • Headline: Split proof-of-concept strategy across CIndU and CSU, but still early and sponsor-heavy in the current evidence layer.
  • Current strategic read: The current local evidence suggests Escient is probing both inducible and spontaneous urticaria rather than staying confined to one subtype, but the support is still relatively thin and manuscript depth is weak.
  • Highest visible phase in current registry: Phase 2
  • Strategy confidence in current local layer: Low

Why this looks like the strategy

  • One early CIndU study and one randomized CSU study are visible, which looks like paired proof-of-concept branching across the broader urticaria space.
  • Because publication support is weak in the local cache, this remains a cautious strategic read rather than a fully triangulated one.

What to watch next

  • Whether future sponsor or conference materials clarify which phenotype has the stronger efficacy story.

Operational study design view

Trial Arms in registry Active dose regimens Total enrollment Per-arm sample size summary
NCT06050928 1 1 33 EP262 150 mg n=33
NCT06077773 4 3 113 ClinicalTrials.gov results-section denominators support placebo n=38, EP262 50 mg n=37, and EP262 150 mg n=38, totaling 113 participants. The posted results note that Part 2 was not enrolled, so the listed EP262 25 mg row remains unresolved in the current local layer.

Study Inventory

Completed / historical studies

  • NCT06050928 - Phase 1; COMPLETED; Chronic Inducible Urticaria
  • NCT06077773 - Phase 2; TERMINATED; Chronic Spontaneous Urticaria

Active / recruiting studies

  • None in current registry

Other registry entries

  • None in current registry

Program Results Summary

Trials with source-backed results in the current local layer: 1 of 2

NCT06077773 (Posted (CT.gov)) - Primary endpoint not met: UAS7 change from baseline at week 6 showed no significant separation from placebo for either EP262 dose. - TEAEs: placebo 12/38 (31.6%), EP262 50 mg 15/37 (40.5%), EP262 150 mg 19/38 (50.0%). - Sources: ClinicalTrials.gov posted results (NCT06077773 resultsSection)

Evidence Coverage

  • CT.gov trials in registry: 2
  • Sponsor artifacts in registry: 1
  • Primary publications in registry: 0
  • Supporting publications in registry: 0
  • Publication status: search_collisions_only
  • Publication summary: The PubMed search returned 3 hits, but title-level review suggests they are broad chronic urticaria reviews rather than direct EP262 manuscripts.

Primary publications

  • No primary publications currently linked in the registry

Supporting evidence

  • No supporting publications currently listed
  • Sponsor artifact: Pipeline page (Escient Pharmaceuticals)
  • raw/sponsors/mrgprx2/ep262/pipeline-page.html
  • raw/sponsors/mrgprx2/ep262/pipeline-page.md

Interpretation

  • Verified facts: the current v2 registry tracks 2 CT.gov entries for this program and links them conservatively to sponsor and publication evidence where explicit identifiers are available.
  • Interpretation: this program is currently supported mainly by CT.gov and/or sponsor-source evidence, with weaker direct manuscript coverage in the local cache.
  • Open questions:
  • Several sponsor artifacts remain program-level because no explicit study identifier was captured in cached metadata.

Provenance

  • Primary source(s):
  • ../inventories/source_registry.json
  • ../inventories/source_registry.md
  • Supporting source(s):
  • ../inventories/ctgov_priority_trials.json
  • ../inventories/publication_priority_curation.json
  • ../inventories/sponsor_priority_sources.json
  • Last verified: 2026-04-08
  • Verification status: Partial

Change Log

  • 2026-04-08: Generated or refreshed this program page from the v2 source registry and local source caches.